Jefferies Group LLC reiterated their buy rating on shares of Patheon NV (NASDAQ:PTHN) in a research report sent to investors on Friday. They currently have a $32.00 price target on the stock, down from their previous price target of $33.00.
Several other research analysts have also recently issued reports on the stock. Zacks Investment Research cut shares of Patheon NV from a hold rating to a sell rating in a report on Friday, December 9th. Robert W. Baird cut shares of Patheon NV from an outperform rating to a neutral rating and cut their target price for the stock from $34.00 to $28.00 in a report on Friday. Three analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company has a consensus rating of Buy and an average price target of $31.30.
Patheon NV (NASDAQ:PTHN) traded down 2.20% on Friday, hitting $26.69. 412,210 shares of the company were exchanged. The company has a market capitalization of $3.87 billion and a price-to-earnings ratio of 104.67. Patheon NV has a 52 week low of $23.72 and a 52 week high of $32.95. The stock has a 50 day moving average of $30.59 and a 200 day moving average of $28.61.
Patheon NV (NASDAQ:PTHN) last issued its earnings results on Thursday, March 16th. The company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by $0.08. The firm had revenue of $457.40 million for the quarter, compared to analysts’ expectations of $463.39 million. During the same quarter last year, the company earned ($0.08) EPS. The business’s revenue was up 12.7% on a year-over-year basis. Analysts predict that Patheon NV will post $1.14 EPS for the current fiscal year.
var userip;Your IP Address: document.write(userip);
Hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. bought a new stake in Patheon NV during the third quarter valued at $91,321,000. TimesSquare Capital Management LLC bought a new stake in Patheon NV during the third quarter valued at $50,137,000. Samlyn Capital LLC bought a new stake in Patheon NV during the third quarter valued at $40,553,000. BlackRock Advisors LLC bought a new stake in Patheon NV during the third quarter valued at $36,634,000. Finally, Citadel Advisors LLC bought a new stake in Patheon NV during the third quarter valued at $31,226,000.
About Patheon NV
Patheon N.V. is a provider of outsourced pharmaceutical development and manufacturing services. The Company’s segments include Drug Product Services (DPS), Pharmaceutical Development Services (PDS) and Drug Substance Services (DSS). The DPS segment is engaged in manufacturing and packaging for approved prescription, over-the-counter (OTC) and nutritional products.
Receive News & Ratings for Patheon NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Patheon NV and related companies with MarketBeat.com's FREE daily email newsletter.